摘要
目的探讨大剂量沐舒坦在合并COPD患者腹部手术术后的应用价值。方法60例合并COPD行腹部手术术后的患者随机分成两组,治疗组(n=30)静脉泵注大剂量沐舒坦(330毫克/次,3次/天,连续5天);对照组(n=30)静脉泵注常规剂量沐舒坦(30毫克/次,3次/天,连续5天)。比较两组患者给药前及给药后第5天氧合指数、血清超氧化物歧化酶(SOD)活性、丙二醛(MDA)水平、总抗氧化能力(T-AOC);观察记录药物不良反应和肺部术后并发症。结果治疗组与对照组在给药前及给药后第5天氧合指数、SOD活性、MDA、T-AOC、肺部并发症方面没有显著性差异(P>0.05);对于给药前氧合指数<200mmHg亚组的病人,给药后第5天治疗组(n=10)与对照组(n=8)比较,氧合指数改善明显(P<0.05),SOD活性、MDA、T-AOC等氧化应激指标有显著性差异(P<0.05)。结论在合并COPD病人腹部手术后应用大剂量沐舒坦未能显示明显益处,但对于术后氧合指数低于200mmHg的亚组患者大剂量沐舒坦可以改善氧合,减轻氧化应激。
Objective To investigate the application value of high - dose ambroxol in COPD patients after abdominal surgery. Methods 60 cases of the COPD patients after abdominal surgery were randomly divided into two groups. The treatment group （n = 30） continuous intravenous infusion of high -dose ambroxol （330mg tidx for 5 days） ; the control group （n = 30） continuous intravenous infusion of conventional doses ambroxol（30mg tidx for 5 days）. Before and 5 days after administration, oxygenation index, serum superoxide dismutase （SOD） activity, malondialdehyde （MDA） levels and total antioxidant capacity （ T - AOC） were compared between two groups of patients. Drug adverse reactions and pulmonary postoperative complications were observed. Results Compared to the control group, the treatment group has no significant difference in oxygenation index, SOD activity, MDA, T -AOC, pulmonary complications before and 5 days after administration. （P 〉 0. 05）. The subgroup patients of the oxygenation index 〈 200mmHg after operation （ n = 10） , compared to the control group （ n = 8） has significant difference in oxygenation index, SOD activity, MDA and T - AOC （P 〈 0.05 ）. Conclusion In COPD patients after abdominal surgery, intravenous infusion of high - dose ambroxol failed to show clear benefit. But for the subgroup patients of less than 200mmHg oxygenation index after operation, intravenous infusion of high - dose ambroxol can improve oxygenation and reducing oxidative stress.
出处
《医学研究杂志》
2009年第6期63-65,共3页
Journal of Medical Research
